Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term
Protection and Sterilizing Immunity in Nonhuman Primates
SEATTLE, May 31, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that a measles DNA vaccine formulatedwith the company's
Vaxfectin(TM) adjuvant elicited protectivelevels of neutralizing antibodies in juvenile (1 - 2 year old)nonhuman primates confirmed by complete protection followingchallenge more than one year after vaccination, and sterilizingimmunity as evidenced by...
Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA
Vaccine Performance; Yields Antibody Responses Comparable to
Electroporation Without Tolerability Issues
MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that in a recently completed animalstudy, a DNA vaccine formulated with the company's patented
Vaxfectin(TM) adjuvant and delivered by needle-free injectionyielded significantly higher antibody responses than anunformulated DNA vaccine delivered by needle and syringe. In aseparate animal study, electro...
Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With
Seasonal Influenza Vaccine
SAN FRANCISCO, April 11, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that a seasonal influenza vaccineformulated with the company's
Vaxfectin(TM) adjuvant generated upto 60-fold higher antibody responses than an unformulated vaccineat the same dose in a recently completed study in mice. Formulationof sanofi pasteur's Fluzone(R) commercial vaccine with
Vaxfectin(TM) al...